Resources Repository
-
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Government/Law | Costing Methods | Benefit-Cost Analysis | Chronic Disease/Risk | Policy/Regulation | Health/Medicine | North America -
Resource PackPublication, Teaching Resource 2017Resource Pack: U.S. Opioid Epidemic
Opioid misuse and addiction in the United States is an ongoing and rapidly evolving public …
Opioid misuse and addiction in the United States is an ongoing and rapidly evolving public health crisis, requiring an urgent coordinated response and innovative scientific solutions. This resource pack was curated for educators and students interested in how decision analytic methods and tools can be applied to the problem of opioid addiction.
Government/Law | Preferences/Values | Evidence Synthesis | Mathematical Models | Decision Analysis | Cost-Effectiveness Analysis | Chronic Disease/Risk | Mental Health | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Health/Medicine | North America | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Decision Making/Leadership | Policy Translation -
ArticlePublication 2016What Determines HIV Prevention Costs at Scale?
Human immunodeficiency virus (HIV) prevention services for key populations are commonly delivered through NGOs. However, …
Human immunodeficiency virus (HIV) prevention services for key populations are commonly delivered through NGOs. However, funding for HIV prevention remains scarce, and there are growing calls internationally to improve the efficiency of HIV prevention programmes as a key strategy to reach global HIV targets. To date, there is limited evidence on the determinants of costs of HIV prevention delivered through NGOs, and thus, policymakers have little guidance in how best to design programmes that are…
Government/Law | Costing Methods | Cost-Effectiveness Analysis | Infectious Diseases | Health Systems | Global Governance | Economics/Finance | Health/Medicine | Asia & Pacific -
GuidelinesPublication 2015USPSTF Procedure Manual
The U.S. Preventive Services Task Force (USPSTF) Procedure Manual describes the methods used by the …
The U.S. Preventive Services Task Force (USPSTF) Procedure Manual describes the methods used by the Task Force to ensure that its recommendations are scientifically sound, reproducible, and well documented. The Manual provides a high-level description of the Task Force’s structure, governance, and processes for selecting topics, reviewing evidence, soliciting and responding to public input, and arriving at a recommendation. It is intended as a guide for anyone who is interested in the Task Force, Task…
Government/Law | Priority Setting/Ethics | Evidence Synthesis | Technology Assessment | Health Systems | Policy/Regulation | Health/Medicine | North America -
GuidelinesPublication 2014Principles of Good Practice for Budget Impact Analysis
This report provides recommendations for conducting a Budget Impact Analysis from the ISPOR 2012 Budget …
This report provides recommendations for conducting a Budget Impact Analysis from the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. National regulatory agencies such as the National Institute for Health and Clinical Excellence in England and Wales and the Pharmaceutical Benefits Advisory Committee in Australia, as well as managed care organizations in the United States, now require that companies submit estimates of both the cost-effectiveness and the likely impact of the new health-care…
Government/Law | Costing Methods | Health/Medicine | Europe -
ArticlePublication 2014'Big Push' To Reduce Maternal Mortality in Uganda and Zambia
In the past decade, “big push” global health initiatives financed by international donors have aimed …
In the past decade, “big push” global health initiatives financed by international donors have aimed to rapidly reach ambitious health targets in low-income countries. The health system impacts of these efforts are infrequently assessed. Saving Mothers, Giving Life is a global public-private partnership that aims to reduce maternal mortality dramatically in one year in eight districts from Uganda and Zambia. The authors evaluate the first six to twelve months of the program’s implementation, its ownership…
Government/Law | Health Outcomes | Health Systems | Health/Medicine | Sub-Saharan Africa -
ReviewPublication 2012Applying Decision Science to Managing National Forests
This publication is an example of the application of decision science to the management of …
This publication is an example of the application of decision science to the management of federal public forests, in particular to meet sustainability goals and multiple use regulations. Through three case studies, the authors describe four stages of a decision analytic approach: problem structuring (framing the problem and defining objectives and evaluation criteria), problem analysis (defining alternatives, evaluating likely consequences, identifying key uncertainties, and analyzing tradeoffs), decision point (identifying the preferred alternative), and implementation and monitoring…
Government/Law | Value of Information | Decision Analysis | Risk Analysis | Social Determinants | Environmental Health | Policy/Regulation | Climate/Environment -
ReviewPublication 2001Modeling for Health Care and Other Policy Decisions: Uses, Roles and Validity
This is a review article of the role of modeling approaches to guide decision making …
This is a review article of the role of modeling approaches to guide decision making in health care and other domains. The role of models to support recommendations on the cost-effective use of medical technologies and pharmaceuticals is controversial. At the heart of the controversy is the degree to which experimental or other empirical evidence should be required prior to model use. The authors argue that the controversy stems in part from a misconception that…
Government/Law | Priority Setting/Ethics | Evidence Synthesis | Mathematical Models | Technology Assessment | Environmental Health | Health Systems | Policy/Regulation | Business/Industry | Climate/Environment | Economics/Finance | Energy/Engineering | Health/Medicine | North America